RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Risk of autoimmune dseases (AD) after human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine immunization in women aged 9 to 25 years in the United Kingdom
An observational cohort study
Willame, C., Rosillon, D., Zima, J., Angelo, MG., Stuurman, A., Vroling, H., van Staa, T., Boggon, R., Bunge, E., Pladevall-Vila, M., & Baril, L. (2015). Risk of autoimmune dseases (AD) after human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine immunization in women aged 9 to 25 years in the United Kingdom: An observational cohort study. Pharmacoepidemiology and Drug Safety, 24(Supplement: 1), 409.
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.